Dr. Michelle Ghert is a Professor in the Department of Orthopaedics at the University of Maryland School of Medicine , with a distinguished career in orthopaedic oncology . She completed her residency at Duke University and fellowship at University of Toronto , and previously held academic appointments at McMaster University from 2005–2017 before joining Maryland in 2024. Education : B.A.S. from Stanford University (1992), MD from Vanderbilt University (1996) Leadership : Principal investigator in international trials like PARITY and SAFETY , shaping sarcoma care standards Her research focuses on musculoskeletal tumor management and complex limb reconstruction , with expertise in randomized controlled trials for surgical and oncology protocols. She has received prestigious awards including the 2023 Kappa Delta Ann Doner Vaughan Award and 2019 J. Édouard Samson Award , and holds active grants from NIH , DOD , and the Canadian Cancer Society .
Paul Johnson, Ph.D. is a Professor in the Biology Department at the University of North Georgia, specifically within the College of Health and Natural Sciences. He maintains an office in the Health and Natural Sciences building, room 435, in Dahlonega. Dr. Johnson teaches several courses including Microbiology for Allied Health Professions, Genetics, Food Microbiology (Study Abroad), Environmental Microbiology, and General Microbiology. Dr. Johnson earned his Ph.D. in Microbiology and Molecular Genetics from Emory University in 2010 and his B.S. in Biology from North Georgia College & State University in 2002. Following his doctoral studies, he completed a Postdoctoral Fellowship at Emory University from 2010-2012. Dr. Johnson's research focuses on understanding bacterial mechanisms for evading antimicrobial agents, specifically differentiating between antibiotic resistance (heritable genetic mechanisms) and antibiotic tolerance/persistence (survival of genetically identical subpopulations). His work primarily utilizes two model organisms: N. gonorrhoeae and S. aureus . This research has important implications for developing more effective antimicrobial therapies and understanding treatment failures. Dr. Johnson has made significant contributions to understanding efflux pumps, gene regulation in pathogenic bacteria, and the molecular mechanisms underlying antibiotic resistance. Analysis of Dr. Johnson's publication record reveals a consistent focus on antimicrobial resistance mechanisms, particularly in Neisseria gonorrhoeae and Staphylococcus aureus . His work spans molecular genetics, bacterial physiology, and the clinical implications of resistance mechanisms. Over time, his research has expanded from basic mechanisms of efflux pumps to broader questions about bacterial persistence and the evolutionary dynamics of resistance development. The interdisciplinary nature of his work connects microbiology, molecular genetics, and clinical medicine. Dr. Johnson serves as an advisor for Biology and Pre-Medicine students at UNG. His expertise in microbiology and antimicrobial resistance informs both his research and teaching, creating a strong connection between his scholarly work and classroom instruction. While specific grant information isn't provided in the available materials, his productive publication record suggests successful research funding. Based on his research focus on N. gonorrhoeae and S. aureus , Dr. Johnson likely maintains laboratory facilities for bacterial culture, genetic manipulation, and antimicrobial susceptibility testing. His work on microbial population dynamics suggests sophisticated experimental approaches to studying bacterial communities and their responses to antimicrobial challenges.
Genhong Cheng is a Professor in the Department of Microbiology, Immunology, and Molecular Genetics (MIMG) at the University of California Los Angeles (UCLA). His research focuses on understanding the molecular mechanisms of host-pathogen interactions, particularly in viral infections such as Zika virus, SARS-CoV-2, and influenza. Dr. Cheng has made significant contributions to the field of innate immunity, especially in interferon signaling pathways and NF-kappaB regulation. Dr. Cheng's research interests span across virology, immunology, and molecular biology. He has extensively studied how viruses interact with host immune responses, with a particular focus on interferon signaling pathways. His work has revealed critical mechanisms by which viruses evade host defenses and how host cells mount effective antiviral responses. Key areas of investigation include: NF-kappaB signaling in immune responses Interferon-stimulated gene functions Host metabolic changes during viral infection Mechanisms of viral replication and evasion Development of broad-spectrum antiviral strategies Analysis of Dr. Cheng's recent publications reveals a strong focus on emerging viral threats, including SARS-CoV-2 and monkeypox virus. His research consistently explores how host metabolic pathways intersect with immune responses to viral infection. A notable theme is the identification of host factors that can be targeted for broad-spectrum antiviral therapies, particularly those involving lipid metabolism and interferon-stimulated genes. Recent work has emphasized translational applications of basic discoveries in viral pathogenesis. Dr. Cheng's laboratory has been instrumental in advancing our understanding of host-pathogen interactions at the molecular level. His team employs a multidisciplinary approach combining virology, immunology, molecular biology, and systems biology to unravel complex host-virus relationships. Current research directions include exploring novel antiviral strategies targeting host factors that are essential for viral replication.
Professor Mark Enright is a Professor of Medical Microbiology at Manchester Metropolitan University's Department of Life Sciences, specializing in genomic epidemiology of antibiotic-resistant pathogens and bacteriophage therapy development. His work bridges clinical microbiology with advanced genomic techniques to combat multidrug-resistant infections. His educational background includes: PhD in Medical Microbiology, University of Aberdeen (1995) MSc in Biochemistry, University of Dundee (1990) BSc (Hons) in Biological Sciences, University of Stirling (1989) Enright's research focuses on antibiotic resistance mechanisms in Gram-positive and Gram-negative pathogens, with groundbreaking work on bacteriophage-based therapeutics targeting Staphylococcus aureus , Pseudomonas aeruginosa , and Klebsiella pneumoniae . His laboratory employs whole-genome sequencing and core-genome MLST to track pathogen evolution, biofilm formation, and horizontal gene transfer. Recent projects include developing phage cocktails against cystic fibrosis-related infections and characterizing depolymerases for capsular polysaccharide degradation. Analysis of his 2015-2025 publications reveals consistent focus on genomic epidemiology of healthcare-associated pathogens, with increasing emphasis on phage therapy applications. His work demonstrates methodological evolution from traditional typing to advanced genomic analyses, particularly in tracking international MRSA transmission and developing phage-based biofilm disruption strategies for wound infections. His major recognitions include: Royal Society University Research Fellowship (2000-2008) European Society for Clinical Microbiology Young Investigator Award (2002) As Editor of the International Journal of Antimicrobial Agents and Section Editor for FEMS Microbiology Letters , Enright shapes antimicrobial research discourse. He serves on editorial boards of Antibiotics and PeerJ , and reviews for Science and Nature . His grant review expertise for Wellcome Trust, MRC, and EU programs informs global research funding priorities. Formerly a Visiting Professor at University of Bath (2011-2014), he maintains strong industry-academia collaborations in antimicrobial development. His Molecular Microbiology teaching integrates cutting-edge research into curriculum, while his John Dalton Building laboratory develops novel approaches to combat antimicrobial resistance through phage genomics and biofilm disruption technologies.
Prof. Henny van der Mei is a Full Professor at the University of Groningen's Faculty of Medical Sciences, affiliated with the Man, Biomaterials and Microbes (MBM) department. His research focuses on biomaterial-associated infections, bacterial adhesion, and biofilm formation. He holds editorial roles at Colloids and Surfaces; Biofilms and FEMS Reviews Microbiology . Research Interests: Van der Mei's work centers on understanding how modified biomaterial surfaces influence bacterial adhesion and biofilm formation. Key areas include antimicrobial strategies for medical implants, nanotechnology applications in infection control, and the development of novel antibiofilm agents. His expertise spans biomaterials science, microbiology, and biomedical engineering. Recent Articles: His most recent studies explore carbon quantum dots for antimicrobial applications, macrophage interactions with Staphylococcus aureus, and single-atom catalysts for antibacterial therapy. He has published over 680 articles, with a focus on biofilm dispersal mechanisms and nanomaterial-based solutions to antibiotic resistance. Awards: While no specific awards are listed, his extensive research output and editorial roles highlight significant contributions to the field. Grants/Advising: Supervised over 100 works and actively participates in global initiatives like the European Water Tech Week. His activities include keynote speaking at conferences on biofilms, biomaterials, and water technology. Labs/Teams: Leads research in antimicrobial biomaterials and biofilm control at the UMCG, collaborating internationally on projects addressing infections in medical devices and water systems.
Xuefei Huang is a Professor in the Departments of Biomedical Engineering and Chemistry at Michigan State University (MSU), serving as Associate Chair for Research in the Chemistry Department. He earned his Ph.D. from Columbia University and previously worked at the University of Toledo. His research integrates synthetic chemistry, biology, and engineering to develop advanced tools for disease diagnosis and treatment, with a focus on carbohydrate chemistry, molecular imaging, and targeted drug delivery. Education: Ph.D., Columbia University Bachelor's degree, University of Science and Technology of China Research Interests: His work emphasizes the synthesis and application of carbohydrates, particularly in developing vaccines, anti-cancer therapies, and diagnostic nanoparticles. Key areas include glycoconjugate vaccines, nanoparticle-based drug delivery systems, and immunotherapies targeting cell surface carbohydrates. The Huang Lab employs interdisciplinary approaches, combining organic synthesis, molecular imaging, and virology. Research Trends in Publications: Recent work focuses on carbohydrate-based vaccines (e.g., SARS-CoV-2, Salmonella), glyco-nanoparticle design for imaging and surgery guidance, and structure-activity relationships in heparin/heparan sulfate oligosaccharides. Labs & Teams: The Huang Lab collaborates across disciplines to advance biomedical innovations, with a focus on translational applications in oncology, infectious diseases, and nanotechnology.
Evgeny A. Idelevich is a Professor at the Institute of Clinical Microbiology and Hospital Hygiene, University Medicine Greifswald, Germany. His expertise spans Clinical Microbiology , Virology , and Infectious Disease Epidemiology , with a focus on Multidrug-Resistant Organisms and Translational Research . Research Interests: Bloodstream infections, rapid diagnostic techniques, Staphylococcus aureus pathogenesis, and healthcare-associated infections. Email: evgeny.idelevich@med.uni-greifswald.de Publications: 10+ studies (2016-2025) on sepsis care, nanopore sequencing, and antimicrobial resistance. His work emphasizes 24-hour microbiology services for critical care and cross-border comparisons of healthcare structures impacting infection control.
Caetano Antunes is an Assistant Professor in the Department of Molecular Biosciences at the University of Kansas, where he joined in January 2023 after transitioning from Fundação Oswaldo Cruz in Rio de Janeiro, Brazil. His research program focuses on host-microbe interactions with particular emphasis on small molecules in the gut metabolome and their effects on bacterial pathogen behavior. Dr. Antunes earned his B.Sc. and M.Sc. in Microbiology from Universidade Federal do Rio de Janeiro (2000, 2002), completed his Ph.D. at the University of Iowa (2007), and conducted post-doctoral research at the University of British Columbia (2008-2012). His work bridges microbiology, metabolomics, and molecular biology to understand how microbial metabolites influence pathogen virulence and host responses. His recent publications reveal a consistent focus on gut microbiome-derived small molecules and their regulatory effects on bacterial pathogens like Salmonella and Vibrio cholerae. His research spans from basic molecular mechanisms to potential therapeutic applications targeting pathogen virulence without directly killing bacteria, representing a promising antivirulence approach to combat antibiotic resistance. Dr. Antunes teaches courses including Introduction to Honors Research, Immunology Laboratory, Rigor and Reproducibility in Research, and Advanced Molecular Genetics, demonstrating his commitment to training the next generation of scientists in both foundational and advanced molecular techniques.
Dr. Michael Leung is a Clinical Senior Lecturer at the University of Western Australia (UWA) within the UWA Medical School's Department of Pathology & Laboratory Medicine. His research focuses on antimicrobial resistance, bacterial pathogenesis, and infectious diseases, contributing to global Sustainable Development Goals related to health and well-being. His work emphasizes clinical microbiology, particularly in areas like Staphylococcus aureus sepsis, Enterococcal infections, and diagnostic challenges such as the prozone phenomenon in cryptococcal assays. He has published extensively on antibiotic resistance surveillance and molecular epidemiology. Lead author on annual reports for the Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) and Enterococcal Sepsis Outcome Programme (AESOP). Contributed to studies on rapid diagnostic methods, such as the FilmArray blood culture system. Leung is involved in two major grants: the FHRI Translation Fellowship (2022–2025) and the AFTERMATH project (2021–2024), focusing on post-pandemic antibiotic resistance preparedness and translational research.
Robin Patel, M.D., is a Professor of Medicine and Microbiology at Mayo Clinic in Rochester, Minnesota. She serves as Director of the Infectious Diseases Research Laboratory, Chair of the Division of Clinical Microbiology, and Director of the Bacteriology Laboratory within the Department of Laboratory Medicine and Pathology. Her work bridges clinical microbiology, infectious diseases, and translational research, with a focus on improving patient care through innovation in diagnostics and therapeutics. Her research interests center on biofilm-mediated infections , including prosthetic joint infections, endocarditis, and catheter-associated infections. She investigates mechanisms of biofilm formation and resistance, develops novel diagnostic assays, and evaluates new antimicrobial agents using in vitro and animal models (e.g., rabbit endocarditis, mouse pneumonia). Her lab is also deeply involved in combating antimicrobial resistance through innovative strategies such as electrochemical bandages and catheters. Dr. Patel's recent publications highlight trends in novel antimicrobial devices , phage therapy , proteomic analysis of biofilms , and advanced molecular diagnostics . Her work increasingly integrates engineering solutions with microbiology to create non-antibiotic interventions for persistent infections. Fellow, American Association for the Advancement of Science (2024) Distinguished Mayo Clinic Investigator (2022) Distinguished Educator Award (2021) Elizabeth P. and Robert E. Allen Professor of Individualized Medicine (2017) Fellow, American Academy of Microbiology (2012) Dr. Patel has led multiple NIH-funded grants, including projects on electrochemical catheters for bloodstream infection prevention and novel bandages for wound infections. She mentors a large research team and contributes significantly to national standards through leadership roles in the American Board of Pathology and Clinical and Laboratory Standards Institute. Her lab collaborates extensively across disciplines and institutions, driving innovation in clinical microbiology and infectious diseases. She is affiliated with key research centers at Mayo Clinic, including the Center for Individualized Medicine, the Infectious Diseases Research Center, and the Center for Clinical and Translational Science (CCaTS). Her laboratory is a hub for translational research, developing assays that are directly implemented in patient care at Mayo Clinic.
Dr. Carola Venturini is a Lecturer at the Sydney School of Veterinary Science, University of Sydney. Her research focuses on microbiology, antimicrobial resistance (AMR), and bacteriophage therapy with a One Health perspective. She holds a BSc (Hons) from the University of Trieste and a PhD in Molecular Biology from the University of Wollongong. Her work investigates mobile genetic elements in bacterial pathogens and explores bacteriophage applications in animal and human health. Education: BSc (Hons) in Natural Sciences, University of Trieste PhD in Molecular Biology, University of Wollongong Research interests include: Evolution of drug-resistant pathogens Horizontal gene transfer mechanisms Bacteriophage-based interventions Microbiome ecology and antibiotic impacts Recent work highlights bacteriophage translocation in human colonoids, Vibrio harveyi pathogenesis in fish, and MDR Klebsiella pneumoniae clonal spread. Her studies bridge animal, human, and environmental health sectors. Grants include projects on phage formulations for animal infections, AMR surveillance in India, and collaborations with institutions in Germany, UK, USA, and Italy. Labs/Teams: Collaborates with the Westmead Institute for Medical Research and maintains international partnerships through the Sydney Southeast Asia Centre and Charles Perkins Centre.
Magnus Höök, PhD, holds the position of Regents & Distinguished Professor and Neva & Wesley West Chair at Texas A&M University. His academic roles include: Adjunct Professor at Baylor College of Medicine Adjunct Professor at University of Texas M.D. Anderson Cancer Center Faculty member at University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences Dr. Höök earned his B.S. in biochemistry and Ph.D. in medical chemistry from Uppsala University (Sweden). His research focuses on microbial adherence mechanisms and host defense evasion, with key areas including: Molecular pathogenesis of infections Extracellular matrix interactions Bacterial virulence factors (e.g., Staphylococcus aureus, Borrelia burgdorferi) Recent work highlights contributions to understanding: Decorin’s role in fibrin assembly Panton-Valentine leukocidin’s role in pneumonia Evolutionary dynamics of bacterial virulence No scientific awards are explicitly listed, though his academic chairs reflect recognition. Advising and grants are not detailed in the text. Dr. Höök leads the Höök Lab, focusing on translational research in infectious disease prevention and treatment.
Lisa A. Beck, M.D. is a Professor in the Department of Dermatology at the University of Rochester Medical Center's School of Medicine and Dentistry. She also holds joint appointments in the Department of Medicine (Allergy/Immunology and Rheumatology) and the Department of Pathology and Laboratory Medicine. As the Lowell A. and Carol A. Goldsmith Professor in Dermatology, Dr. Beck brings over 25 years of experience specializing in atopic dermatitis and eczema treatment and research. She serves as Co-Director of the URMC Center for Allergic Disease Research, which holds the World Allergy Organization's Center of Excellence designation. MD: State University of New York at Stony Brook (1985) Residency: Internal Medicine, University of Rochester Medical Center (1985-1986) Residency: Dermatology, Duke University Medical Center (1987-1990) Fellowship: Research, Johns Hopkins Hospital (1992-1994) Dr. Beck's research has been instrumental in developing dupilumab (Dupixent), the first biologic drug approved for moderate to severe eczema. Her work focuses on understanding why certain eczema patients are susceptible to viral infections like herpes simplex and bacterial colonization with Staphylococcus aureus. She has been continuously NIH-funded since 1994 and serves as co-PI of the NIH/NIAID-funded Atopic Dermatitis Research Network (ADRN) since 2004, which maintains the largest cross-sectional registry of deeply phenotyped AD subjects worldwide. Dr. Beck is Secretary of the International Eczema Council and President-Elect of the Society of Investigative Dermatology. Analysis of Dr. Beck's recent publications reveals a strong focus on biologic treatments for atopic dermatitis, particularly dupilumab, and their effects on inflammatory biomarkers, patient outcomes, and long-term disease management. Her work increasingly examines the relationship between skin barrier dysfunction, microbiome interactions, and immune responses in eczema pathogenesis. Recent studies also address specialized populations including pregnant women and children, reflecting a growing emphasis on tailored treatment approaches across the lifespan. Dermatology Faculty Teaching Award (2008) Mentor for multiple research grant recipients (2005-2007) Physician-Scientist Award (1994) Research Award (1994) Teaching Appreciation Award (1992) Internal Medicine Teaching Award (1992) Dr. Beck has maintained continuous NIH funding since 1994, serving as co-PI of the Atopic Dermatitis Research Network since 2004 and PI of the ADRN Biomarker Repository since 2014, which houses over 150,000 serum and skin swab samples. As founding director of the URMC Dermatology Clinical Trials Unit, she has completed more than 14 clinical trials with exceptional enrollment and retention rates, maintaining a registry of over 500 atopic dermatitis patients. Her mentorship has supported numerous young investigators through Howard Hughes, AAAAI, and NEASE research grants. Dr. Beck co-directs the URMC Center for Allergic Disease Research (CADR), one of only four US centers designated as a World Allergy Organization Center of Excellence. She leads the Atopic Dermatitis Research Network, which maintains the largest registry of deeply phenotyped atopic dermatitis subjects globally. Her laboratory investigates skin barrier function, viral susceptibility mechanisms, and the relationship between skin microbiome and immune responses in atopic dermatitis pathogenesis.
Carolyn Ibberson serves as an Assistant Professor of Microbiology at the University of Oklahoma, where she leads the Ibberson Lab focused on bacterial physiology in chronic human infections. Her research program addresses fundamental questions about how pathogens like Staphylococcus aureus establish and persist in chronic infections, with particular emphasis on polymicrobial interactions. B.S. in Biology from University of Wisconsin-Madison (2010) Ph.D. in Microbiology from University of Iowa (2015) Postdoctoral training at University of Texas at Austin (2015-2017) and Georgia Institute of Technology (2017-2021) Dr. Ibberson's research focuses on understanding bacterial physiology during human infection, particularly examining how co-infecting microbes influence S. aureus behavior and disease severity. Her work bridges classic microbiology with advanced genomic and computational approaches to address why chronic polymicrobial infections are notoriously difficult to treat, representing a significant healthcare burden costing over $20 billion annually in the United States. Her laboratory employs next-generation sequencing, microscopy, computational pipelines, and deep learning to investigate the molecular mechanisms of bacterial persistence and microbe-microbe interactions in chronic infection settings. Analysis of Dr. Ibberson's publications reveals a consistent focus on bacterial pathogenesis, particularly Staphylococcus aureus and Pseudomonas aeruginosa in human infections. Her work spans transcriptomics, biofilm formation, virulence factor regulation, and polymicrobial interactions, demonstrating an interdisciplinary approach that combines molecular microbiology with ecological and evolutionary perspectives. Her research trajectory shows increasing sophistication in methodologies, incorporating advanced genomic techniques and computational analysis to address complex questions in infection biology. Dr. Ibberson maintains an active research program through the Ibberson Lab at the University of Oklahoma, where she mentors students and collaborators in cutting-edge microbiological research. While specific grant information isn't detailed in the available materials, her publication record suggests successful funding for research on bacterial physiology in chronic infections, polymicrobial communities, and pathogen adaptation mechanisms. Her work has significant implications for developing new therapeutic approaches for difficult-to-treat chronic infections. The Ibberson Lab represents a dynamic research environment focused on understanding the fundamental biology of bacterial pathogens in clinically relevant contexts. The lab's work on spatial structure in microbial communities, host-pathogen interactions, and gene regulation during infection provides critical insights that could lead to novel antimicrobial strategies targeting the complex ecology of chronic infections.
Krystle J. McLaughlin is an Associate Professor of Chemistry at Vassar College, where she has been since 2017. She earned a B.A. in Physics from Colgate University (2006) and a PhD in Biophysics from the University of Rochester (2011), followed by a postdoctoral fellowship in pedagogical training and research at the University of North Carolina at Chapel Hill’s SPIRE program. Her research focuses on biochemical and biophysical studies of microbial proteins, particularly antibiotic resistance mechanisms in pathogens like Staphylococcus and Salmonella , using protein x-ray crystallography and cryo-electron microscopy. She is an elected member of the US National Committee for Crystallography. Teaching responsibilities include Biochemistry (Chem 272), Biophysical Chemistry (Chem 326), and Protein Crystallography (Chem 295). McLaughlin’s lab emphasizes undergraduate research, with recent grants including a 2022 Cottrell Scholar Award ($100,000) supporting research and teaching development. She has balanced her career with motherhood, leveraging tenure-clock extensions and childcare arrangements during the pandemic. Her pandemic-era innovations include recorded lectures and iPad-based teaching tools to enhance accessibility. Her research articles span structural biology of bacterial enzymes, conjugative proteins, and gut microbiome enzymes. McLaughlin collaborates on initiatives to improve STEM education equity, including developing course-based research experiences (CUREs) and placement tests for incoming chemistry students.
